Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)

van Santen, Daniela K; Stewart, Ashleigh; Doyle, Joseph S; Stoove, Mark A; Asselin, Jason; Klein, Marina B; Young, Jim; Berenguer, Juan; Jarrin, Inmaculada; Lacombe, Karine; Wittkop, Linda; Leleux, Olivier; Salmon, Dominique; Bonnet, Fabrice; Rauch, Andri; Mugglin, Catrina; Matthews, Gail; Prins, Maria; Smit, Colette; Boyd, Anders; van der Valk, Marc; Sacks-Davis, Rachel; Hellard, Margaret E; Group, InCHEHC Study

doi:10.26181/25255498.v1

Cohort Profile: International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)

journal contribution

posted on 2024-02-21, 04:22 authored by Daniela K van Santen, Ashleigh StewartAshleigh Stewart, Joseph S Doyle, Mark A Stoove, Jason Asselin, Marina B Klein, Jim Young, Juan Berenguer, Inmaculada Jarrin, Karine Lacombe, Linda Wittkop, Olivier Leleux, Dominique Salmon, Fabrice Bonnet, Andri Rauch, Catrina Mugglin, Gail Matthews, Maria Prins, Colette Smit, Anders Boyd, Marc van der Valk, Rachel Sacks-Davis, Margaret E Hellard, InCHEHC Study Group

Key Features:

- The International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC) is a multinational consortium of longitudinal cohorts of people with HIV who are at risk of hepatitis C virus (HCV) infection or infected with HCV. InCHEHC has been specifically designed to assess progress towards HCV elimination as a public health threat among people with HIV.

- The first data merge includes 104 740 participants from 11 cohorts in Australia (n = 22 033), Canada (n = 2070), France (n = 18 387), The Netherlands (n = 24 785), Spain (n = 16 725) and Switzerland (n = 20 740), with data collected between 1987 and 2021. Participants include 86 132 males (81.4%), 19 514 females (18.4%) and 191 with unknown sex at birth (0.2%); 725 (1.0%) were known to be transgender across eight cohorts collecting data on this variable. At enrolment, the median age was 38 years (interquartile range: 30–46). Of the total 104 740 participants, 12 784 (12%) had an HCV antibody or RNA positive test at or up to 1 year prior to individual cohort enrolment; 32 360 (31%) did not have an HCV RNA or antibody test recorded at that time.

- Clinical data are collected on all participants and behavioural and mortality data on a subset of them. Clinical data include HIV-related markers, HCV testing and treatment, liver health-related markers and sexually transmitted and blood-borne virus co-infections. Behavioural data include sexual and injecting risk behaviours and alcohol and drug use. Mortality data are collected using the International Classification of Diseases 9th or 10th revision (ICD-9/10) or Coding Causes of Death in HIV (CoDE) classification.

- Data are available by request from the InCHEHC steering committee. Initial requests should be directed to Rachel Sacks-Davis (rachel.sacks-davis@burnet.edu.au).

Funding

This study was funded by the Australian Government National Health and Medical Research Council (grant numbers GNT1132902 and GNT2020121). We gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.

History

Publication Date

2024-02-01

Journal

International Journal of Epidemiology

Volume

53

Issue

1

Article Number

dyad154

Pagination

17p.

Publisher

Oxford University Press

ISSN

0300-5771

Rights Statement

© The Author(s) 2023. Published by Oxford University Press on behalf of the International Epidemiological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com